### **Overview** Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the **largest pharmaceutical company in India** and the **world’s fourth-largest specialty generics company**, with a diversified global footprint across **over 100 countries**. Headquartered in Mumbai, the company operates through a vertically integrated model—spanning research, development, manufacturing, and commercialization—delivering high-quality, affordable medicines in chronic and acute therapeutic areas. With a strong focus on **specialty pharmaceuticals, generics, consumer healthcare, and active pharmaceutical ingredients (APIs)**, Sun Pharma serves a broad patient base through its advanced manufacturing capabilities, innovative R&D pipeline, and extensive commercial infrastructure. --- ### **Business Segments & Revenue Streams (FY25)** Sun Pharma’s global operations are organized across several key segments: | Segment | FY25 Sales (INR Million) | % of Revenue | Key Contributions | |--------|--------------------------|------------|-------------------| | **India** | ₹169,230 | ~33% | Market leader with 8.3% share; highest field force productivity; broad portfolio in chronic and acute care. | | **United States** | ₹162,403 | ~31% | Ranked 12th in generics; #2 in dermatology by prescriptions; key contributor to generics and specialty growth. | | **Emerging Markets** | ₹94,160 | ~18% | Operations in ~80 countries; focus on Romania, Russia, South Africa, Brazil, and Mexico. | | **Rest of World (RoW)** | ₹71,626 | ~14% | Markets include Western Europe, Canada, Japan, Israel, Australia & New Zealand. | | **API Business** | ₹21,292 | ~5% | Supplies ~400 APIs to global generics and innovator firms; 401 DMF/CEP approvals. | > *Exports accounted for ~75% of total turnover, reflecting deep international integration.* --- ### **Strategic Focus & Growth Drivers** #### **1. Global Specialty Business: A High-Growth Engine** - **Contribution**: ~20% of FY25 revenue, up from 9% in FY20. - **Therapeutic Focus**: Dermatology, Ophthalmology, and Oncodermatology. - **Key Products**: - **ILUMYA (tildrakizumab)**: IL-23 inhibitor for plaque psoriasis; Phase-3 trials ongoing for psoriatic arthritis (data expected late 2025). - **LEQSELVI (deuruxolitinib)**: FDA-approved JAK inhibitor for severe alopecia areata; 95% of patients reported satisfaction with hair regrowth. - **WINLEVI (clascoterone)**: First-in-class topical androgen receptor inhibitor for acne vulgaris. - **CEQUA (cyclosporine)**: First FDA-approved nanomicellar treatment for dry eye disease. - **ODOMZO (sonidegib)**: Hedgehog pathway inhibitor for advanced basal cell carcinoma. - **Recent Acquisitions**: - **Checkpoint Therapeutics (Mar/May 2025)**: Added **UNLOXCYT™** (anti-PD-L1 therapy), the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma. - **Concert Pharmaceuticals (FY23–25)**: Strengthened dermatology pipeline with **deuruxolitinib** (LEQSELVI). > Sun Pharma now markets **26 innovative specialty products globally**, with the U.S. being the largest revenue contributor. #### **2. R&D and Innovation** - **R&D Investment**: ₹32 billion in FY25 (~6.2% of sales), up from ₹31.8 billion in FY24; consistent investment of 6–8% annually planned. - **R&D Centers**: Six global hubs with **over 2,900 scientists**. - **Pipeline (as of Oct 2025)**: - **19 projects**: 11 pre-clinical, 5 in clinical trials (1 Phase I, 2 Phase II, 2 Phase III), 2 ready for launch. - **7 clinical-stage specialty candidates**, including **Nidlegy™** (L19IL2/L19TNF), **Fibromun** (L19TNF) in registration for sarcoma and glioblastoma (via Philogen licensing). - **No first-in-class or expedited review products** currently in pipeline. > Strategic alliances with **Philogen (2024–25)** for immunotherapy assets underscore growing innovation ambitions. #### **3. Product Portfolio & Therapeutic Strengths** - **Branded Generics & Generics**: Wide coverage in CNS, cardiology, diabetes, gastroenterology, anti-infectives, oncology, and respiratory. - **Consumer Healthcare**: Top 10 in India, Nigeria, Romania, and Myanmar; key brands include **Revital, Volini, Abzorb**. Available in ~500,000 Indian retail outlets. - **OTC Expansion**: Strong OTC presence with topical analgesics, vitamins, cough & cold products across >25 countries; brands like **Proactiv** (acquired via Taro/Alchemee) in U.S., Canada, Japan. --- ### **Manufacturing & Supply Chain** - **Global Manufacturing**: **42 facilities** (as of Oct 2025), including: - **26** finished dosage units. - **14 dedicated API facilities**. - **Capabilities**: Full integration in oncology, peptides, steroids, hormones, controlled substances; dosage forms include oral, injectables, sprays, creams, ointments, and drug-device combinations. - **Regulatory Approvals**: Facilities approved by **USFDA, EMA, MHRA, TGA, PMDA, and WHO**. - **Supply Chain Strategy**: - Localization and onshore/offshore integration to reduce import dependency. - Inventory buffers for critical inputs; proactive trade policy advocacy to mitigate tariff risks. --- ### **Global Subsidiaries & Market Presence** Sun Pharma operates through a robust international subsidiary network, including: - **Ranbaxy Inc. (USA)** - **Taro Pharmaceutical Industries Ltd.** (100% subsidiary since FY24): Key for U.S. dermatology and OTC. - **Pola Pharma (Japan)**: Entry into Japanese dermatology market (2019). - Entities in **Russia, Spain, Malaysia, Brazil, Australia, Canada, and Romania**. > Local manufacturing in **8 key markets**, including Bangladesh, South Africa, Nigeria, and Mexico, supports regional supply chain resilience. --- ### **India Business: Market Leadership** - **Revenue**: ₹169,230 million (FY25), up 13.7% YoY. - **Market Share**: 8.3% (up from 8.0% in FY24), based on MAT data (Mar 2025). - **Sales Force**: Largest and most productive field force in India; >12,000 representatives for enhanced tier-II & tier-III outreach. - **Portfolio**: - 29 brands in India’s top 300 prescriptions. - 42 new product launches in FY25. - Focus on chronic therapies: neuropsychiatry, cardiology, diabetes, anti-infectives. - **Strategy**: Growth via volume expansion, new launches, and specialty product in-licensing (e.g., VORTIDIF™ for depression via Lundbeck). --- ### **Emerging Markets & International Reach** - **Countries**: ~80 markets; key focus on **Romania, Russia, South Africa, Brazil, and Mexico**. - **Revenue**: ₹94.2 billion (FY25), up 9.2% YoY. - **Local Presence**: Manufacturing in 8 countries; over **2,900 sales reps**. - **Growth Model**: Branded generics, broad distribution, and market-specific commercial execution. --- ### **Recent Strategic Developments (2025)** - **May 2025**: Completed acquisition of Checkpoint Therapeutics; launched **UNLOXCYT™** for cSCC. - **October 2024**: Signed exclusive global agreement with **Philogen** for **Fibromun (L19TNF)** in soft tissue sarcoma and glioblastoma. - **2025 Pipeline Catalysts**: - **Phase-3 data** for ILUMYA in psoriatic arthritis (expected H2 2025). - **Nidlegy™** under EMA review for melanoma; potential approval in EU/ANZ. - **Fibromun** in late-stage trials; first-in-class immunotherapy with global commercial rights. ---